141 related articles for article (PubMed ID: 32722951)
1. Effects of adenosine triphosphate on vandetanib induced skin damage in rats.
Akagunduz B; Ozcicek F; Kara AV; Guven DC; Yazici GN; Çoban A; Suleyman B; Mammadov R; Suleyman H
Cutan Ocul Toxicol; 2020 Dec; 39(4):323-327. PubMed ID: 32722951
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of adenosine triphosphate against sunitinib-related skin damage in rats.
Yıldırım N; Karatas A; Cengiz M; Onalan E; Yazıcı GN; Sunar M; Mammadov R; Coban A; Suleyman H
Hum Exp Toxicol; 2020 Dec; 39(12):1737-1746. PubMed ID: 32677474
[TBL] [Abstract][Full Text] [Related]
3. The effect of adenosine triphosphate on sunitinib-induced cardiac injury in rats.
Aldemir MN; Simsek M; Kara AV; Ozcicek F; Mammadov R; Yazıcı GN; Sunar M; Coskun R; Gulaboglu M; Suleyman H
Hum Exp Toxicol; 2020 Aug; 39(8):1046-1053. PubMed ID: 32131635
[TBL] [Abstract][Full Text] [Related]
4. The protective effect of carvacrol on bevacizumab-related skin injury in rats: a biochemical and histopathological evaluation.
Gore Karaali M; Karaali S; Demir D; Yazıcı GN; Coban A; Mammadov R; Suleyman B; Suleyman H
Cutan Ocul Toxicol; 2022 Dec; 41(4):285-290. PubMed ID: 36111398
[TBL] [Abstract][Full Text] [Related]
5. Effects of adenosine triphosphate on methanol-induced experimental optic nerve damage in rats: biochemical and histopathological evaluation.
Icel E; Suleyman H; Yazici GN; Bakan N; Sunar M
Cutan Ocul Toxicol; 2020 Sep; 39(3):244-248. PubMed ID: 32543996
[TBL] [Abstract][Full Text] [Related]
6. Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Jin Y; Chen X; Gao Z; Shen X; Fu H; Pan Z; Yan H; Yang B; He Q; Xu Z; Luo P
Biomed Pharmacother; 2021 Dec; 144():112297. PubMed ID: 34649218
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
8. Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats.
Akbaş N; Akbaş EM; Süleyman Z; Çiçek B; Ağgül AG; Mokhtare B; Süleyman H
Cutan Ocul Toxicol; 2023 Mar; 42(1):32-37. PubMed ID: 36656642
[TBL] [Abstract][Full Text] [Related]
9. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
10. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
11. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
12. Effect of adenosine triphosphate, benidipine and their combinations on bevacizumab-induced kidney damage in rats.
Kocaturk H; Bedir F; Turangezli Ö; Arslan R; Çoban TA; Altuner D; Suleyman H
Adv Clin Exp Med; 2021 Nov; 30(11):1175-1183. PubMed ID: 34595851
[TBL] [Abstract][Full Text] [Related]
13. The safety of vandetanib for the treatment of thyroid cancer.
Tsang VH; Robinson BG; Learoyd DL
Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
[TBL] [Abstract][Full Text] [Related]
17. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
18. Vandetanib: too dangerous in medullary thyroid cancer.
Prescrire Int; 2012 Oct; 21(131):233. PubMed ID: 23185843
[TBL] [Abstract][Full Text] [Related]
19. Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.
Arriola-Villalobos P; Benito-Pascual B; Díaz-Valle D; Benítez-Del-Castillo JM
Cornea; 2018 Jun; 37(6):789-792. PubMed ID: 29521690
[TBL] [Abstract][Full Text] [Related]
20. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.
Massicotte MH; Borget I; Broutin S; Baracos VE; Leboulleux S; Baudin E; Paci A; Deroussent A; Schlumberger M; Antoun S
J Clin Endocrinol Metab; 2013 Jun; 98(6):2401-8. PubMed ID: 23543666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
